Regeneron and Sanofi Announce Intent to Restructure Antibody Collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

(STL.News) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced their intent to simplify their antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab) by restructuring into a royalty-based agreement.  Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent.  Regeneron is expected to gain sole U.S. rights to Praluent.  Under the proposed terms of the agreement, each party will be solely responsible for funding development and commercialization expenses in their respective territories.  These changes are expected to increase efficiency and streamline operations for the products.  The existing collaboration relating to Dupixent® (dupilumab) will remain unchanged following the restructuring.  Completion of the proposed arrangement is expected to be finalized in the first quarter of 2020.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.  Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.  Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, including VelocImmune® which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

CLICK to VIEW SOURCE